Document is current
Any future updates will be listed below
-
Authors
Curtis, Jeffrey R.
Herrem, Christopher
Ndlovu, ’Matladi N.
O’Brien, Cathy
Yazici, Yusuf
-
Funding
Funding for this research was provided by:
UCB Pharma
-
More Information
Article History
Received: 9 May 2017
Accepted: 29 August 2017
First Online: 29 September 2017
Ethics approval and consent to participate
: The study protocol, amendments, and patient informed consent were reviewed by a national, regional, or Independent Ethics Committee (IEC) or Institutional Review Board (IRB). Patient informed consent was conducted in accordance with the current version of the applicable regulatory and International Conference on Harmonization (ICH) Good Clinical Practice (GCP) requirements, the ethical principles that have their origin in the principles of the Declaration of Helsinki, and the local laws of the countries involved.
: Not applicable.
: JRC: research grants and consulting fees from UCB Pharma, Janssen, CORRONA, Amgen, Pfizer, Bristol-Myers Squibb, Crescendo Bioscience. CH: Medical Director at Mylan, former employee of UCB Pharma. MNN: employee of UCB Pharma. COB: employee of UCB Pharma. YY: research grants from Bristol-Myers Squibb, Genentech, Celgene; consulting fees from Bristol-Myers Squibb, Celgene, Samumed.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
